Prosurg's Opal goes on sale:
This article was originally published in Clinica
Prosurg's Opal probe for the treatment of urological and gynaecological disorders is poised for worldwide distribution. The California-based company introduced its outpatient needle ablation electrosurgical device at the recent American Urological Association meeting in Orlando. The probe, which has already received 510(k) clearance from the US FDA, can deliver anaesthetic agents or biomaterials to the tissue prior to radio frequency energy treatment and is compatible with diagnostic endoscopes.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.